Imeglimin治疗2型糖尿病：印度背景下的专家意见和共识
Imeglimin in Type 2 Diabetes Mellitus: Expert Opinions and Consensus in Indian Context.
摘要(中文译文)
我们饶有兴趣地阅读了Seshadri等关于imeglimin用于2型糖尿病（T2DM）管理的专家共识。该文及时且信息丰富，尤其考虑到印度糖尿病管理日益增加的复杂性。关于imeglimin新型机制的讨论——该机制通过线粒体途径同时针对胰岛素抵抗和线粒体功能障碍——得到了很好的总结，并与日益强调保护β细胞功能的趋势相一致。
Abstract
We read with interest the expert consensus by Seshadri et al. on imeglimin for the management of type 2 diabetes mellitus (T2DM). The article is timely and informative, particularly in view of the increasing complexity of diabetes management in India. The debate around the novel mechanism of imeglimin, which addresses both insulin resistance and mitochondrial dysfunction through mitochondrial routes, is well summarized and is in line with the increasing emphasis on preserving the function of the beta cell..
如何引用
AMA
Jegan Duraiswamy, Nitin Chintaman Gawari, Tanvi Naik, Teja Achyut Deshpande. Imeglimin in Type 2 Diabetes Mellitus: Expert Opinions and Consensus in Indian Context.. The Journal of the Association of Physicians of India. 2026; doi:10.59556/japi.74.1567.
APA
Jegan Duraiswamy, Nitin Chintaman Gawari, Tanvi Naik, Teja Achyut Deshpande (2026). Imeglimin in Type 2 Diabetes Mellitus: Expert Opinions and Consensus in Indian Context.. The Journal of the Association of Physicians of India. https://doi.org/10.59556/japi.74.1567
GB/T 7714
Jegan Duraiswamy, Nitin Chintaman Gawari, Tanvi Naik, Teja Achyut Deshpande. Imeglimin in Type 2 Diabetes Mellitus: Expert Opinions and Consensus in Indian Context.[J]. The Journal of the Association of Physicians of India, 2026 doi:10.59556/japi.74.1567.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出